US pharma major Eli Lilly (NYSE: LLY) today announced the second multi-billion dollar acquisition of the New Year, saying it had reached a definitive agreement to acquire Loxo Oncology (Nasdaq: LOXO), with the news sending the latter’s shares up about 63.8% at $229 in pre-market trading today. Lilly was down 2.67% at $111.60 pre-market.
Lilly is offering $235.00 per share in cash, which represents a premium of about 68% to Loxo’s Friday close, or around $8.0 billion. Loxo Oncology is a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers.
Just last week, Bristol-Myers Squibb (NYSE: BMY) kicked off the MA& season with a $74 billion bid for Celgene (Nasdaq: CELG).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze